Open Medicine (May 2024)
Cost-effectiveness of ambroxol in the treatment of Gaucher disease type 2
Abstract
Our aim was to compare the costs and efficacy of ambroxol in combination with imiglucerase with the costs and efficacy of imiglucerase only in the treatment of Gaucher disease type 2 (GD2) in the socio-economic settings of the Republic of Serbia, an upper-middle-income European economy.
Keywords